Spermidine Has the Cleanest Mechanism in the Longevity Aisle. The Only Year-Long Human Trial Raised the Dose by Ten Percent and Found Nothing.
Most longevity supplements fail in the same boring way. The mechanism is vague, the mouse data comes from one lab, and the human trial that eventually runs is small enough to explain away. Spermidine fails differently, which is what makes it worth a careful read. Its mechanism is not vague at all: spermidine triggers autophagy, the cellular recycling process, and when researchers deleted the autophagy gene Atg5 from mouse heart muscle, spermidine's cardiac benefit vanished completely. That is a mechanistic demonstration by subtraction, and very few supplements have one. The epidemiology is unusually clean too. Then the trials arrive, and the story stops. This article is about the gap between a molecule that works in every model organism anyone has tested and a supplement aisle that has yet to produce a single positive human outcome, and about the absorption problem sitting quietly underneath the whole category.
Key Takeaways: What the Spermidine Evidence Actually Shows
Spermidine is a naturally occurring polyamine found in food, made by the body, and present in every cell, with wheat germ the richest common dietary source at roughly 24 to 35 mg per 100 grams according to food composition surveys. Eisenberg and colleagues reported in Nature Medicine in November 2016 that oral spermidine extended median lifespan in mice, reduced cardiac hypertrophy, preserved diastolic function in old animals, and lowered systemic blood pressure in Dahl salt-sensitive rats fed a high-salt diet, with the cardiac benefit disappearing entirely in mice lacking the autophagy protein Atg5 in cardiomyocytes. The Bruneck study, a community cohort of 829 Italian adults aged 45 to 84 with dietary assessment between 1995 and 2010 and mortality follow-up through 2015, reported a hazard ratio for all-cause death of 0.74 per one standard deviation higher spermidine intake adjusted for age, sex and calories, and 0.76 after further adjustment for lifestyle and diet. SmartAge, published in JAMA Network Open in May 2022, randomized 100 adults aged 60 to 90 with subjective cognitive decline to 0.9 mg of spermidine per day from wheat germ extract or placebo for 12 months and found no benefit on its primary memory endpoint, with a between-group difference of minus 0.03 and a 95 percent confidence interval of minus 0.11 to 0.05 at a p value of 0.47, and no benefit on any prespecified secondary endpoint. The SmartAge authors noted that their dose added only about 10 percent to a participant's average daily spermidine intake. A 2023 crossover study in Nutrients gave 12 healthy adults 15 mg of spermidine daily for 5 days and found plasma spermidine did not rise, though plasma spermine did at a p value of 0.0282, and proposed that oral spermidine is converted almost entirely to spermine in the intestinal wall or on first pass through the liver. A 2024 trial in Nutrition Research gave 40 mg per day for up to 28 days to 37 healthy men aged 50 to 70 and reported no substantial change in serum or urine polyamine concentrations, alongside excellent safety and tolerability. Dietary spermidine intake showed no association with prostate cancer incidence in 54,517 men in the PLCO screening trial, at a relative risk of 1.00 comparing the highest to lowest quintile. No randomized trial has shown that spermidine supplementation improves a clinical outcome in humans, and no analysis has examined testosterone, fertility or any male hormonal endpoint.
What is spermidine and why do longevity researchers care about it?
Spermidine is a small polyamine molecule that your cells already make, that circulates in your tissues, and that you eat every day without thinking about it. Researchers care about it because it is one of the most reliable pharmacological triggers of autophagy known, and autophagy is the process by which a cell breaks down and recycles its own damaged components. Autophagy declines with age across essentially every organism studied, and restoring it is the shared mechanism behind several of the better-supported longevity interventions, including caloric restriction and rapamycin. Spermidine reaches the same target from a different direction, and it does so as a nutrient rather than a drug. The dietary angle is genuinely unusual. Wheat germ carries roughly 24 to 35 mg per 100 grams and is the richest commonly available source. Fermented soy products such as natto, aged cheeses, mushrooms, legumes and cruciferous vegetables all contribute meaningful amounts, generally in the range of 2 to 20 mg per 100 grams depending on the food and how it was processed. The gut microbiome produces spermidine as well, which means total exposure is not simply a function of what is on the plate. A person eating a varied diet takes in something on the order of 9 mg per day, a figure implied by the SmartAge investigators when they described their 0.9 mg supplement as adding about 10 percent to habitual intake. That number matters more than it first appears, because it sets the scale against which every supplement dose has to be judged.
How strong is the animal evidence for spermidine?
The animal evidence is strong, consistent across species, and unusually well mechanistically anchored. Spermidine extends lifespan in yeast, nematode worms, fruit flies and mice, which is a breadth few candidate compounds match. The pivotal mouse paper is Eisenberg and colleagues in Nature Medicine in November 2016, volume 22, issue 12, which reported that oral spermidine supplementation extended median lifespan in mice and produced a set of cardiac effects that go well beyond a survival curve. Old mice given spermidine showed reduced cardiac hypertrophy and preserved diastolic function, the measure of how well a heart relaxes and fills, which is precisely the function that deteriorates in the most common form of heart failure in older adults. The mechanism findings are where this paper separates itself. Spermidine feeding increased cardiac autophagy, mitophagy and mitochondrial respiration, improved the mechanical and elastic properties of heart muscle cells in living animals, increased phosphorylation of titin, the giant spring protein that governs cardiac stiffness, and suppressed low-grade inflammation. Then the researchers deleted Atg5, a gene essential for autophagy, specifically from cardiomyocytes. In those mice, spermidine feeding produced no cardioprotection at all. That is the key experiment, because it converts a plausible story about autophagy into a demonstrated dependency. The same paper extended the work into Dahl salt-sensitive rats fed a high-salt diet, a model of hypertension-driven congestive heart failure, where spermidine reduced systemic blood pressure, prevented cardiac hypertrophy and blocked the decline in diastolic function. Blood pressure, structure and function all moved in the same direction in a second species.
The Spermidine Record on One Axis
Every strand of the spermidine case arranged as a single schematic map. Green marks what the evidence supports, amber marks design limits that are real without being disqualifying, slate marks findings that count against the supplement, and dark grey marks claims the evidence does not carry. Spermidine has the cleanest mechanism in the longevity supplement aisle: it triggers autophagy, and when the autophagy gene Atg5 is deleted from mouse heart muscle the cardiac benefit disappears entirely. That is the kind of result most candidates never produce. What spermidine does not yet have is a single human trial showing that swallowing it changes an outcome, and a pharmacology problem sits underneath that gap, because oral spermidine largely fails to arrive in the blood as spermidine.
What does the human observational evidence show?
The observational evidence points the same way as the animal work and is the reason spermidine became a commercial supplement at all. The central dataset is the Bruneck study, a community-based cohort of 829 adults aged 45 to 84 living in an alpine town in northern Italy, with dietician-administered dietary questionnaires collected between 1995 and 2010 and mortality follow-up continuing through 2015. Higher dietary spermidine intake was associated with substantially lower risk of dying. Each one standard deviation increase in intake carried a hazard ratio for all-cause death of 0.74 with a 95 percent confidence interval of 0.66 to 0.83, adjusted for age, sex and caloric intake. Adding adjustment for lifestyle factors and other features of the diet moved the estimate only slightly, to 0.76 with a confidence interval of 0.67 to 0.86. An effect that survives that much adjustment is not nothing. It is also not a trial. The structural problem with dietary spermidine epidemiology is harder than usual, because the foods richest in spermidine are wheat germ, legumes, mushrooms, fermented soy and aged cheese, and people who eat a lot of those foods differ from people who do not in ways no questionnaire fully captures. A high-spermidine diet is close to a proxy for a whole-food, plant-heavy, minimally processed eating pattern. Whether the polyamine is doing the work or simply riding along with the dietary pattern is exactly the question observational data cannot answer, and it is exactly the question a randomized trial exists to settle.
A Striking Cohort Result and a Flat Trial
Effect estimates from the two kinds of human evidence, with the dashed line at 1.0 marking no effect. Bars below the line favour spermidine. The Bruneck study followed 829 residents of an Italian alpine town aged 45 to 84, assessed diet by questionnaire between 1995 and 2010, and tracked deaths through 2015: each one standard deviation increase in dietary spermidine intake carried a hazard ratio for all-cause death of 0.74 adjusted for age, sex and calories, and 0.76 after further adjustment for lifestyle and other dietary factors. SmartAge, the only 12-month randomized placebo-controlled trial, found no difference from placebo on its primary memory endpoint or on any prespecified secondary endpoint, and is plotted flat at 1.0. People who eat more spermidine live longer. Giving people slightly more spermidine has not yet changed anything measurable.
What happened in SmartAge, the only twelve-month randomized trial?
SmartAge found nothing. The trial was published in JAMA Network Open in May 2022 and randomized 100 adults aged 60 to 90 with subjective cognitive decline, 51 to spermidine and 49 to placebo, with 89 completing the full 12 months. The cohort was almost evenly split by sex at 49 percent female, with a mean age of 69, and compliance was excellent at 95.3 percent. Participants took 750 mg of wheat germ extract daily, delivering 0.9 mg of spermidine. The primary endpoint was mnemonic discrimination performance on the Mnemonic Similarity Task, a memory test sensitive to early hippocampal change. The result was a between-group difference of minus 0.03, with a 95 percent confidence interval running from minus 0.11 to 0.05 and a p value of 0.47. That is not a near miss or an underpowered signal pointing the right way. It is a flat line centred on zero. No prespecified secondary endpoint showed a treatment effect in the intention-to-treat analysis either. Exploratory per-protocol analyses hinted at movement in the inflammation marker sICAM-1 and in Trail Making Test B performance, and those are the findings supplement marketing tends to quote, but exploratory per-protocol results from a trial that missed its primary endpoint are hypotheses at best. The safety picture was reassuring in a way that deserves its own mention: adverse events were balanced between arms at 58 in the spermidine group against 71 on placebo, with 7 serious adverse events on spermidine and 12 on placebo. Whatever else this trial demonstrated, it demonstrated that a year of supplementation is well tolerated.
The Trial That Ran Longest Used the Smallest Dose
Daily spermidine dose in each of the main human supplementation studies, in milligrams. SmartAge is the only 12-month randomized trial with a cognitive endpoint, and it used 0.9 mg per day from 750 mg of wheat germ extract, which its own authors described as adding roughly 10 percent to a participant's habitual daily intake. That implies a background dietary intake near 9 mg per day, shown in amber. The two studies that actually pushed the dose well above diet, at 15 mg and 40 mg per day, were short pharmacokinetic and safety studies lasting 5 and 28 days, neither designed to measure whether anything improves. Nobody has yet run a long trial at a dose that clearly exceeds what people already eat.
- Milligrams per day
Was the SmartAge dose too small to work?
Probably, and the trial's own authors said so. SmartAge delivered 0.9 mg of spermidine per day, which the investigators described as roughly 10 percent of average daily intake. Framed plainly, the trial asked whether adding a tenth of a person's normal spermidine consumption for a year would change their memory, and the answer was no. That is a legitimate answer to a narrow question, and it is a poor test of the broader hypothesis that spermidine matters. The comparison with the animal work makes the mismatch obvious. Mouse studies deliver spermidine at concentrations in drinking water that correspond to exposures far above anything a 0.9 mg capsule provides on a body-weight basis. The Bruneck cohort finding was driven by differences in habitual intake between people eating very different diets, not by a 10 percent increment. The authors listed two further limitations that compound the dose problem. Their participants were cognitively healthy with subjective complaints rather than measurable decline, so there was very little deterioration for a treatment to slow over 12 months, and amyloid biomarker data was available in only about 30 percent of the sample. A null result in a barely declining cohort given a barely detectable dose is weak evidence against spermidine. What it is not is evidence for spermidine, and the commercial products on the shelf today are mostly sold at doses in the same range SmartAge tested.
One Measurement Moved Out of Six
Whether each measured polyamine pool actually changed after oral spermidine, scored as moved or did not move. In the 2023 Nutrients crossover study, 12 healthy adults took 15 mg of spermidine per day for 5 days: plasma spermine rose significantly at p equals 0.0282, while plasma spermidine, salivary spermidine and salivary spermine all stayed flat. In the 2024 Nutrition Research trial, 37 men aged 50 to 70 took 40 mg per day for up to 28 days and the investigators reported no substantial change in serum or urine polyamine concentrations. The proposed explanation is that spermidine taken by mouth is converted almost entirely into spermine inside the intestinal wall or on first pass through the liver, so what a capsule delivers to the bloodstream is not the molecule on the label.
Does swallowing spermidine actually raise spermidine in the blood?
Largely no, and this is the finding that reframes the entire supplement category. A randomized, placebo-controlled, triple-blinded crossover study published in Nutrients in 2023 gave 12 healthy adults 15 mg of spermidine per day for 5-day intervention phases and measured plasma and saliva. Plasma spermidine did not increase significantly. Plasma spermine did increase, at a p value of 0.0282, and salivary spermidine and spermine both stayed flat. The authors proposed a specific explanation: after uptake into intestinal cells, spermidine is almost completely converted into spermine, either within the enterocytes themselves or during first-pass metabolism in the liver. Under that model an oral spermidine capsule behaves as a prodrug for spermine rather than as a delivery vehicle for spermidine, and human absorption differs meaningfully from the rodent situation the animal literature is built on. The higher-dose data points the same way. A randomized, double-blind, within-subject placebo-controlled trial published in Nutrition Research in 2024 gave 37 healthy men aged 50 to 70 a high-purity spermidine trihydrochloride supplement at 40 mg per day for up to 28 days, more than 40 times the SmartAge dose. There were no significant changes in clinical chemistry, lipids or haematology, no product-related adverse events, and no substantial change in serum or urine polyamine concentrations. The investigators interpreted the flat polyamine readings as evidence of effective homeostatic control, meaning the body actively regulates polyamine levels rather than letting dietary intake set them. That interpretation is plausible and it is also a problem, because a supplement that cannot move the measurement it is named after faces a hard question about how it would produce a benefit.
The Prostate Question, Answered in 54,517 Men
Relative risks comparing the highest to the lowest quintile of dietary spermidine intake among 54,517 men with a mean age of 62 in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, published in 2026. Over a median follow-up of about 14 to 15 years the cohort accumulated 6,643 prostate cancer diagnoses and 603 prostate cancer deaths. Incidence showed no association at a relative risk of exactly 1.00 with a confidence interval of 0.89 to 1.12. Prostate cancer specific mortality came in at 1.24 with a confidence interval of 0.96 to 1.60 and a p value of 0.10, which crosses 1.0 and does not reach significance. The concern this addresses is real in principle, because prostate tissue runs unusually high polyamine synthesis, but at dietary levels of intake the association is not there.
Is spermidine safe for men, and does it affect the prostate?
Dietary spermidine intake showed no association with prostate cancer incidence in the largest analysis available, and the safety profile in trials has been consistently unremarkable. The prostate question deserves to be asked rather than waved away, because prostate tissue runs unusually high polyamine synthesis, ornithine decarboxylase expression is elevated in prostate cancer tissue compared with benign tissue, and dysregulated polyamine metabolism is a recognised feature of prostate cancer biology. That is a real mechanistic reason for a man over 40 to want data before taking a polyamine supplement daily. The data arrived in 2026 from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, covering 54,517 men with a mean age of 62 and a median follow-up of roughly 14 to 15 years, during which the cohort accumulated 6,643 prostate cancer diagnoses and 603 prostate cancer deaths. Comparing the highest to the lowest quintile of dietary spermidine intake, the relative risk for prostate cancer incidence was exactly 1.00 with a confidence interval of 0.89 to 1.12. Prostate cancer specific mortality came in at 1.24 with a confidence interval of 0.96 to 1.60 and a p value of 0.10, an estimate that crosses 1.0 and does not reach statistical significance, though it is not so far from the line that it should be described as reassuring without qualification. Worth keeping straight is that this analysis measured dietary intake, not supplementation, so it speaks to eating wheat germ and natto rather than to taking concentrated capsules. On general safety the trial record is good. SmartAge ran a full year with adverse events balanced against placebo, and the 40 mg per day study in older men found no product-related adverse events across 28 days. This article is educational and is not medical advice.
What should a man over 40 actually do with this evidence?
Eat the foods and hold the supplement loosely, because the dietary evidence is the part with human outcomes attached and the capsule evidence is the part that keeps coming back flat. The honest summary of spermidine is that it has the best mechanistic case and the worst clinical record of anything in this category. The Atg5 knockout experiment is genuinely excellent science. The Bruneck hazard ratio of 0.76 is a serious observational signal. Neither of those has yet converted into a single randomized human trial showing that a person who takes spermidine is better off, and the absorption studies suggest a reason why that conversion has been slow. Three practical points follow. First, if the Bruneck association is causal, it was generated by dietary intake, and wheat germ, natto, aged cheese, mushrooms, legumes and cruciferous vegetables deliver spermidine in the food matrix that generated the signal, at a cost of essentially nothing. Second, if you do take a supplement, understand what you are buying: most products sit near the SmartAge dose that produced a null result over 12 months, higher-dose products have been shown to be safe but not to raise circulating spermidine, and no product has demonstrated a clinical benefit. Third, the gaps that matter most to men are still open. No spermidine analysis has examined testosterone, sex hormone binding globulin, fertility or body composition, so anyone reaching for it as a hormonal or physique intervention is extrapolating past the evidence entirely. Better data is coming. POLYCAD, a Danish randomized double-blind placebo-controlled trial testing high-dose spermidine in older patients with coronary artery disease, completed recruitment in August 2025 with final study visits expected in August 2026, and it is measuring cardiac remodelling, exercise capacity, muscle mass and systemic inflammation, which are outcomes a person can feel. That trial is testing the hypothesis the mouse hearts generated, at a dose that might actually count. Anyone with a history of cancer, anyone taking prescription medication, and anyone considering daily supplementation rather than dietary change should discuss it with a physician first.
Frequently Asked Questions
Have more questions? Contact us or explore our full peptide intelligence platform.
Related Articles
Does Telomere Length Determine Lifespan? Short Telomeres Track With Earlier Death. The Genetics Say Longer Ones Raise Cancer Risk.
Does telomere length determine lifespan? Short telomeres track with earlier death, yet genetic studies show longer ones raise the risk of several cancers.
Low-Dose Aspirin Added 8 Percent to Male Mouse Lifespan. In 19,114 Healthy Older Adults, It Added No Healthy Years and Deaths Ran Higher.
Does low-dose aspirin help longevity? It extended male mouse lifespan 8%, but the ASPREE trial in 19,114 healthy older adults found no gain and more bleeding.
Is NAD+ a Peptide? No. It Is a Coenzyme Built From Two Nucleotides, and the Peptide Label Comes From the Clinic, Not the Chemistry
Is NAD+ a peptide? No. NAD+ is a coenzyme built from two nucleotides. What NAD+ is used for, what IV NAD+ studies found, and how it differs from SS-31.